Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00899990

Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Clinical Trial

Official title:
A COG Study for Collecting and Banking Ewing Sarcoma Specimens

Clinical Trial Summary

This research study is collecting and storing samples of tumor tissue, bone marrow, and blood from patients with Ewing sarcoma. Collecting and storing samples of tumor tissue, bone marrow, and blood from patients with cancer to test in the laboratory may help the study of cancer in the future.

Clinical Trial Description

OBJECTIVES: I. Collect biological specimens, including associated demographic and clinical data, from patients with Ewing sarcoma. II. Provide a repository for long-term storage of Ewing sarcoma-related biological materials. III. Make collected specimens available to qualified researchers to understand the biology of Ewing sarcoma and correlate these results with demographic and clinical data. OUTLINE: This is a multicenter study. Patients undergo collection of tumor specimens, bone marrow, and peripheral blood at diagnosis. Associated demographic and clinical data are collected and archived. Patients who are not enrolled on a therapeutic clinical trial are followed annually. ;

Study Design

Related Conditions & MeSH terms

  • Askin Tumor
  • Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
  • Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
  • Neuroectodermal Tumors
  • Neuroectodermal Tumors, Primitive
  • Neuroectodermal Tumors, Primitive, Peripheral
  • Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
  • Sarcoma
  • Sarcoma, Ewing
Clinical Trial Details
NCT number NCT00899990
Study type Observational
Source Children's Oncology Group
Contact
Status Completed
Phase
Start date February 4, 2008
Completion date September 30, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT00093821 - Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors Phase 1
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT00091182 - Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Phase 2
Completed NCT00004078 - Irinotecan in Treating Children With Refractory Solid Tumors Phase 2
Completed NCT00004241 - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma Phase 1
Completed NCT00030667 - Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood Phase 2
Completed NCT02116777 - Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Phase 1/Phase 2
Completed NCT02304458 - Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Phase 1/Phase 2
Completed NCT00101270 - Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT03210714 - Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Withdrawn NCT02011126 - Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Phase 2
Completed NCT00536601 - High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors N/A
Completed NCT01154452 - Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Phase 1/Phase 2
Completed NCT00330421 - Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) Phase 2
Completed NCT01614795 - Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Phase 2
Withdrawn NCT01795430 - Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma N/A
Completed NCT00609141 - IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor Phase 1
Active, not recruiting NCT00112463 - Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Phase 2
Completed NCT00048984 - Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma N/A
Active, not recruiting NCT00638898 - Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor Phase 1